Back to Results
First PageMeta Content
Bacteria / Extensively drug-resistant tuberculosis / Multi-drug-resistant tuberculosis / Directly Observed Therapy – Short Course / AIDS / Mycobacterium tuberculosis / Drug resistance / The Global Fund to Fight AIDS / Tuberculosis and Malaria / Tuberculosis in China / Tuberculosis / Health / Medicine


Microsoft Word - A62_20-en.doc
Add to Reading List

Document Date: 2009-04-17 01:50:52

Open Document

File Size: 43,84 KB

Share Result on Facebook

City

Geneva / /

Company

Global Laboratory / Stop TB Partnership / /

Continent

Africa / Asia / /

Country

Belarus / Myanmar / Estonia / Bulgaria / Bangladesh / Tajikistan / Kyrgyzstan / Armenia / Latvia / South Africa / Kazakhstan / Congo / Indonesia / Russia / Uzbekistan / Azerbaijan / Pakistan / Moldova / Nigeria / China / Philippines / Georgia / Lithuania / Ethiopia / Ukraine / India / /

Currency

USD / /

Facility

International Drug Purchase Facility / /

IndustryTerm

laboratory infrastructure / retail pharmacies / pharmaceutical industry / results within hours without complex equipment / Manufacturing processes / programmatic management / treatment services / tuberculosis management / weak general health systems / Weak national health systems / health systems / /

MedicalCondition

TB / HIV / adequately funded tuberculosis / drug-resistant tuberculosis / multidrug-resistant tuberculosis / HIV infection / priority multidrug-resistant tuberculosis / disease / communicable diseases / Malaria / Mycobacterium tuberculosis / collaborative tuberculosis / both drug-susceptible and drugresistant disease / AIDS / infection / extensively drug-resistant tuberculosis / tuberculosis / basic tuberculosis / /

MedicalTreatment

antibiotics / /

Organization

Health Assembly / World Health Organization / Executive Board / Global Fund / World Health Assembly / Green Light Committee / /

Product

kanamycin / isoniazid / /

Region

sub-Saharan Africa / central Asia / eastern Europe / /

Technology

diagnostic tests / /

SocialTag